Osteopore (ASX:OSX) announces leadership changes with key appointments

• Hon. Michael Keenan joins the Board as Non-Executive Director
• Dr. Lim Jing promoted to Chief Executive Officer (CEO)
• Mr. Goh Khoon Seng appointed as Global Marketing Director
• Osteopore (OSX) is trading up 3.8 per cent at 8.2 cents

Australian-Singaporean medical technology company Osteopore (OSX) has announced changes to its leadership team with the addition of Hon. Michael Keenan as Non-Executive Director, and the promotion of Dr Lim Jing to CEO.

“Today’s appointments mark a significant strengthening of the leadership team at Osteopore and align with the growth ambitions that we have set for ourselves,” Osteopore’s Executive Chairman Mark Leong said.

The newly appointment Hon. Michael Keenan echoed Leong’s sentiments.

“Being in the regenerative medicine space, the tissue regeneration technology being pioneered by the Company is incredibly exciting and has outstanding potential,” Keenan said.

Hon Keenan is a former WA politician.

Dr. Lim Jing reiterated his commitment to driving growth and working closely with the existing team in the handover process to his new role, to enhance the global adoption of Osteopore’s products.

Osteopore aims to make a significant impact in the medical technology sector.

Osteopore (OSX) last traded up 3.8 per cent at 8.2 cents